A Phase 2 interventional study of Lorlatinib in Carcinoma, Non-Small-Cell Lung, sponsored by Pfizer. Completed at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-05.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 16 under way, 1 of them phase 3. lorlatinib · Carcinoma, Non-Small-Cell Lung.
Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 2 that started in 2019, is one of 16 in phase 2, and was the 8th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →8 of the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:
Chugai Pharmaceutical · Sites in United States, Japan
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Pfizer · Sites in France
Ages 18+
Centro di Riferimento Oncologico - Aviano · Sites in Italy
Ages 18+
Guangdong Association of Clinical Trials · Sites in China
Ages 18+
By country, each count listing its studies:
lorlatinib: first FDA approval 2018 (LORBRENA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 1 · Phase 4 3
First in 2014; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 45 across the 27 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 27 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer: 15 open now, 26 under way, 5 of them phase 3. Of 123 finished, 70 (57%) have results posted.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 58th largest by enrollment of the 136 interventional ones that give a count, is one of 7 that started in 2019, is one of 45 in phase 2, and was the 87th registered.
Pfizer’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
1 of the studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07083687Hunan Cancer HospitalLorlatinib in ROS1+ NSCLC With Brain Metastasis | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 158 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic ALK positive non small cell lung cancer patients in China
This is a Phase 2, China only, multi center, open label, dual cohort study, in ALK positive locally advanced or metastatic NSCLC patients will be enrolled to receive lorlatinib monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject should have:
All Subjects must have at least 1 measurable extracranial target lesion according to v1.1 that has not been previously irradiated. are allowed if:
Adequate bone marrow functions:
Adequate pancreatic function:
Adequate renal function:
a. Serum creatinine 1.5 x ULN or estimated 60 mL/min as calculated using the method standard for the institution.
Adequate liver function:
Serum or urine pregnancy test (for females of ) negative at screening. Female subjects of non childbearing potential must meet at least 1 of the following criteria:
Exclusion Criteria:
Subjects with any of the following characteristics/conditions will not be included in the study:
More than 1 prior chemotherapy regimen prior to enrollment in advanced/ setting.
If disease recurred/ within the chemotherapy treatment or \<=6 months after the completion of the adjuvant chemotherapy, then the adjuvant chemotherapy is considered as the systemic chemotherapy to the disease.
Clinically significant cardiovascular disease (both arterial and venous) and non vascular cardiac conditions, (active or within 3 months prior to enrollment, which may include, but not are limited to:
Concurrent use of any of the following food or drugs (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days prior to the first dose of administration of lorlatinib:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
Drug: Lorlatinib
ALK inhibitor-treated ALK-positive NSCL treatment
Also known as: PF-06463922
Percentage of Participants With Objective Response (Cohort 1)
Objective response rate (ORR) was defined as the percentage of participants with a best overall confirmed response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR was defined as a greater than equal to (\>=) 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Independent Central Radiology (ICR) was used for disease progression assessment.
Time frame: From Cycle 1 Day 1 to documented progression of disease by ICR (up to 67 weeks)
Percentage of Participants With Objective Response (Cohort 2)
ORR was defined as the percentage of participants with a best overall confirmed response of CR or PR according to RECIST version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. ICR was used for disease progression assessment.
Time frame: From Cycle 1 Day 1 to documented progression of disease by ICR (up to 67 weeks)
Progression-Free Survival (PFS) Based on ICR Assessment
PFS was defined as the time from first dose to first documentation of objective disease progression (PD) or to death due to any cause, whichever came first. PD: at least a \>=20 percent (%) increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, PD was defined as unequivocal progression of existing non-target lesions, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Analysis was performed using Kaplan Meier method. ICR was used for disease progression assessment.
Time frame: From first dose (Cycle 1 Day 1) to documented PD by ICR, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)
Progression-Free Survival Based on Investigator Assessment
PFS was defined as the time from first dose to first documentation of objective PD or to death due to any cause, whichever came first. PD: at least a \>=20 % increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, PD was defined as unequivocal progression of existing non-target lesions, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Analysis was performed using Kaplan Meier method. Investigator assessment was used for disease progression assessment.
Time frame: From first dose (Cycle 1 Day 1) to documented progression of disease by investigator, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)
Overall Survival
Overall survival was defined as the time from first dose to the date of death due to any cause. Analysis was performed using Kaplan Meier method.
Time frame: From first dose (Cycle 1 Day 1) to date of death due to any cause (up to 271 weeks of treatment exposure)
Percentage of Participants With Intracranial Objective Response (IC-OR) Based on ICR Assessment
IC-OR: percentage of participants with a best overall confirmed intracranial response of CR or PR according to RECIST version 1.1 relative to total participants in the analysis population but limited to intra cranial lesions only in participants with central nervous system metastases. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>= 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. 95% CI was based on Clopper-Pearson method.
Time frame: From first dose (Cycle 1 Day 1) to documented PD by ICR (up to 271 weeks of treatment exposure)
Percentage of Participants With Intracranial Objective Response Based on Investigator Assessment
IC-OR: percentage of participants with a best overall confirmed intracranial response of CR or PR according to RECIST version 1.1 relative to total participants in the analysis population but limited to intra cranial lesions only in participants with central nervous system metastases. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>= 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. 95% CI was based on Clopper-Pearson method
Time frame: From first dose (Cycle 1 Day 1) to documented progression of disease by investigator (up to 271 weeks of treatment exposure)
Duration of Response (DOR) Based on ICR Assessment
DOR: time from first documentation of CR or PR to first documentation of PD or death due to any cause, whichever occurred first. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm. PR:\>=30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. PD:\>=20 % increase in sum of longest dimensions of target lesions taking as a reference smallest sum of longest dimensions recorded since treatment started, or the appearance of one or more new lesions. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5 mm and for non-target lesions PD: unequivocal progression of existing non-target lesions or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at time of analysis were censored at date of last tumor assessment. Analysis was performed using Kaplan Meier method.
Time frame: From first documentation of CR or PR to documented progression of disease by ICR, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)
DOR Based on Investigator Assessment
DOR: time from first documentation of CR or PR to first documentation of PD or death due to any cause, whichever occurred first. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm. PR:\>=30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. PD:\>=20 % increase in sum of longest dimensions of target lesions taking as a reference smallest sum of longest dimensions recorded since treatment started, or the appearance of one or more new lesions. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5 mm and for non-target lesions PD: unequivocal progression of existing non-target lesions or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at time of analysis were censored at date of last tumor assessment. Analysis was performed using Kaplan Meier method.
Time frame: From first documentation of CR or PR to documented PD by investigator, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure
Duration of Intracranial Response Based on ICR Assessment
Duration of intracranial response: time from first documentation of CR or PR considering only lesions having disease site=brain to first documentation of PD or death due to any cause, whichever occurred first, participants who had at least 1 intracranial lesion.CR: disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in \<10mm.PR:\>=30% decrease in the sum of the longest dimensions of target lesions taking reference the baseline sum longest dimension. PD:\>=20% increase in sum of longest dimensions of target lesion, or appearance of one or more new lesion. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5mm and for non-target lesion PD: unequivocal progression of existing non-target lesion, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan Meier method was used.
Time frame: From first documentation of CR or PR to documented progression of disease by ICR, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)
Duration of Intracranial Response Based on Investigator Assessment
Duration of intracranial response: time from first documentation of CR or PR considering only lesions having disease site=brain to first documentation of PD or death due to any cause, whichever occurred first, participants who had at least 1 intracranial lesion.CR: disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in \<10mm.PR:\>=30% decrease in the sum of the longest dimensions of target lesions taking reference the baseline sum longest dimension. PD:\>=20% increase in sum of longest dimensions of target lesion or appearance of one or more new lesion. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5mm and for non-target lesion PD: unequivocal progression of existing non-target lesion, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan Meier method was used.
Time frame: From first documentation of CR or PR to documented progression of disease by investigator, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)
Time to Tumor Response Based on ICR Assessment
Time to tumor response was defined as the time from first dose to first documentation of objective tumor response CR or PR. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: From first dose (Cycle 1 Day 1) to first documented CR or PR (up to 271 weeks of treatment exposure)
Time to Tumor Response Based on Investigator Assessment
Time to tumor response was defined as the time from first dose to first documentation of objective tumor response CR or PR. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: From first dose (Cycle 1 Day 1) to documented first CR or PR (up to 271 weeks of treatment exposure)
Number of Participants With Adverse Events (AEs)
AE:any untoward medical occurrence in a study participant administered a product or medical device;event did not necessarily have a causal relationship with treatment or usage.Serious AE:any untoward medical occurrence at any dose resulted in death;life-threatening;required inpatient or prolongation of existing hospitalization;persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important event.AEs were graded by the National Cancer Institute Common Terminology Criteria AE(NCICTCAE)v4.03 where,Grade(G)1:mild AE;G2:moderate;G3:severe;G4:life-threatening consequences,urgent intervention indicated;G5:death related to AE. Focus of AE summaries was on treatment-emergent AE(TEAE).AE was considered TEAE if the event occurred during the on-treatment period.On-treatment:time from first dose of study treatment through end of study follow-up(i.e.,up to 28 days after last dose of treatment. Participant with G3or4 and5 AEs were reported.
Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Number of Participants With Central Nervous System-Related Adverse Events
An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily have a causal relationship with the treatment or usage. The central-nervous system-related AEs included AEs under the cluster terms of mood effects, cognitive effects, psychotic effects, and speech effects.
Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities
Laboratory tests included hematology, chemistry and lipids. Laboratory test results were graded according to NCI CTCAE version 4.03, where Grade 0: no AE, Grade 1 : mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Shifts from Grade \<=2 at baseline to Grade 3 or 4 post-baseline were considered clinically significant. Only categories with non-zero values were reported in this outcome measure.
Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria
Vital signs evaluation included diastolic blood pressure (DBP), systolic blood pressure (SBP), pulse rate and weight. Blood pressure and pulse rate were recorded in sitting position after the participant had been sitting quietly for at least 5 minutes. The pre-specified criteria included: sitting SBP change \>=40 millimeters of mercury (mmHg) increase, \>=40 mmHg decrease; sitting DBP change \>=20 mmHg increase, change \>=20 mmHg decrease, or change \>=60 mmHg increase; sitting pulse rate value \<50 beats per minute (bpm), \>120 bpm, change \>=30 bpm increase, or change \>=30 bpm decrease; weight 10% \<= change \<20% increase, change \>=20% increase or change \>=10% decrease. One participant can have more than one vital sign data meeting pre-specified criteria.
Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria
The QT intervals were corrected for heart rate (QTc) using standard correction factors (ie, QTcF \[Fridericia's\], QTcB \[Bazett's\], and possibly a study-specified factor, as appropriate). The pre-specified criteria included: PR interval change \>= 50% and baseline \<200 msec, change \>=25% and baseline \>=200 msec; QRS interval change \>=50% and baseline \<100 msec, change \>=25% and baseline \>=100 msec; QTcB values \<=450 msec, 450 \< Value \<= 480 msec, 480 \< Value \<= 500 msec, value \>500 msec, change \<=30 msec, 30 \< Change \<= 60 msec, change \>60 msec; QTcF value \<=450 msec, 450 \< Value \<= 480 msec, 480 \< Value \<= 500 msec, Value \> 500 msec, change \<=30 msec, 30 \< Change \<=60 msec and change \>60 msec. . One participant can have more than one ECG data meeting pre-specified criteria.
Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Number of Participants With Left Ventricular Ejection Fraction (LVEF) Meeting Pre-specified Criteria
Echocardiogram or multigated acquisition scan were performed to monitor LVEF. Pre-specified criteria included shift from baseline normal to post-baseline below lower limit of normal (LLN) \>=20-point decrease from baseline in LVEF% .
Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Cycle 1 Day 1 Maximum Plasma Concentration (Cmax)
The loratinib Cmax was estimated using non-compartmental analysis.
Time frame: At pre-dose, 0.5, 1, 2, 3, 4, 6 ,8, 9 and 24 hours on Cycle 1 Day 1
Cycle 1 Day 1 Time to Cmax (Tmax)
The loratinib Tmax was estimated using non-compartmental analysis.
Time frame: At pre-dose, 0.5, 1, 2, 3, 4, 6 ,8, 9 and 24 hours on Cycle 1 Day 1
Cycle 1 Day 1 Area Under the Plasma Concentration Versus Time Profile Within A Dose Interval (AUCtau)
The loratinib AUCtau was estimated using non-compartmental analysis.
Time frame: At pre-dose, 0.5, 1, 2, 3, 4, 6 ,8, 9 and 24 hours on Cycle 1 Day 1
Steady-State Cmax
The loratinib Cmax was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.
Time frame: At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1
Steady-State Tmax
The loratinib Tmax was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.
Time frame: At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1
Steady-State AUCtau
The loratinib AUCtau was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.
Time frame: At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1
Apparent Clearance (CL/F)
The loratinib CL/F was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.
Time frame: At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1
Observed Accumulation Ratio (Rac)
The loratinib Rac was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.
Time frame: At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1
Percentage of Participants With Objective Response (Cohort 1)-Final Analysis
ORR was defined as the percentage of participants with a best overall confirmed response of CR or PR according to RECIST version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. ICR was used for disease progression assessment.
Time frame: From first dose (Cycle 1 Day 1) to documented disease progression by ICR (up to 271 weeks of treatment exposure)
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 67 | 42 |
| Completed | 0 | 0 |
| Not completed | 67 | 42 |
| Withdrew: Participant transition to rollover study | 26 | 9 |
| Withdrew: Global deterioration of health status | 2 | 2 |
| Withdrew: Progressive disease | 28 | 21 |
| Withdrew: Death | 6 | 6 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Participant was unwilling to come to site visit | 0 | 1 |
| Withdrew: No longer benefit from lorlatinib | 2 | 0 |
Objective response rate (ORR) was defined as the percentage of participants with a best overall confirmed response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR was defined as a greater than equal to (\>=) 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Independent Central Radiology (ICR) was used for disease progression assessment.
| Percentage of participants | Cohort 1 |
|---|---|
| Percentage of Participants With Objective Response (Cohort 1) | 70.1 (57.7 to 80.7) |
ORR was defined as the percentage of participants with a best overall confirmed response of CR or PR according to RECIST version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. ICR was used for disease progression assessment.
| Percentage of participants | Cohort 1 |
|---|---|
| Percentage of Participants With Objective Response (Cohort 1)-Final Analysis | 79.1 (67.4 to 88.1) |
ORR was defined as the percentage of participants with a best overall confirmed response of CR or PR according to RECIST version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. ICR was used for disease progression assessment.
| Percentage of participants | Cohort 2 |
|---|---|
| Percentage of Participants With Objective Response (Cohort 2) | 47.6 (32.0 to 63.6) |
PFS was defined as the time from first dose to first documentation of objective disease progression (PD) or to death due to any cause, whichever came first. PD: at least a \>=20 percent (%) increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, PD was defined as unequivocal progression of existing non-target lesions, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Analysis was performed using Kaplan Meier method. ICR was used for disease progression assessment.
| Months | Cohort 1 | Cohort 2 |
|---|---|---|
| Progression-Free Survival (PFS) Based on ICR Assessment | 26.3 (16.6 to NA) | 5.6 (2.9 to 12.4) |
PFS was defined as the time from first dose to first documentation of objective PD or to death due to any cause, whichever came first. PD: at least a \>=20 % increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, PD was defined as unequivocal progression of existing non-target lesions, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Analysis was performed using Kaplan Meier method. Investigator assessment was used for disease progression assessment.
| Months | Cohort 1 | Cohort 2 |
|---|---|---|
| Progression-Free Survival Based on Investigator Assessment | 26.3 (15.2 to 52.4) | 6.9 (4.2 to 13.7) |
Overall survival was defined as the time from first dose to the date of death due to any cause. Analysis was performed using Kaplan Meier method.
| Months | Cohort 1 | Cohort 2 |
|---|---|---|
| Overall Survival | NA (42.7 to NA) | 21.9 (11.9 to 44.1) |
IC-OR: percentage of participants with a best overall confirmed intracranial response of CR or PR according to RECIST version 1.1 relative to total participants in the analysis population but limited to intra cranial lesions only in participants with central nervous system metastases. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>= 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Percentage of Participants With Intracranial Objective Response (IC-OR) Based on ICR Assessment | 83.8 (68.0 to 93.8) | 50.0 (28.2 to 71.8) |
IC-OR: percentage of participants with a best overall confirmed intracranial response of CR or PR according to RECIST version 1.1 relative to total participants in the analysis population but limited to intra cranial lesions only in participants with central nervous system metastases. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>= 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. 95% CI was based on Clopper-Pearson method
| Percentage of participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Percentage of Participants With Intracranial Objective Response Based on Investigator Assessment | 63.4 (46.9 to 77.9) | 33.3 (15.6 to 55.3) |
DOR: time from first documentation of CR or PR to first documentation of PD or death due to any cause, whichever occurred first. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm. PR:\>=30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. PD:\>=20 % increase in sum of longest dimensions of target lesions taking as a reference smallest sum of longest dimensions recorded since treatment started, or the appearance of one or more new lesions. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5 mm and for non-target lesions PD: unequivocal progression of existing non-target lesions or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at time of analysis were censored at date of last tumor assessment. Analysis was performed using Kaplan Meier method.
| Months | Cohort 1 | Cohort 2 |
|---|---|---|
| Duration of Response (DOR) Based on ICR Assessment | 31.7 (18.0 to NA) | 10.4 (2.9 to NA) |
DOR: time from first documentation of CR or PR to first documentation of PD or death due to any cause, whichever occurred first. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm. PR:\>=30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. PD:\>=20 % increase in sum of longest dimensions of target lesions taking as a reference smallest sum of longest dimensions recorded since treatment started, or the appearance of one or more new lesions. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5 mm and for non-target lesions PD: unequivocal progression of existing non-target lesions or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at time of analysis were censored at date of last tumor assessment. Analysis was performed using Kaplan Meier method.
| Months | Cohort 1 | Cohort 2 |
|---|---|---|
| DOR Based on Investigator Assessment | 20.9 (12.4 to NA) | 20.8 (5.6 to NA) |
Duration of intracranial response: time from first documentation of CR or PR considering only lesions having disease site=brain to first documentation of PD or death due to any cause, whichever occurred first, participants who had at least 1 intracranial lesion.CR: disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in \<10mm.PR:\>=30% decrease in the sum of the longest dimensions of target lesions taking reference the baseline sum longest dimension. PD:\>=20% increase in sum of longest dimensions of target lesion, or appearance of one or more new lesion. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5mm and for non-target lesion PD: unequivocal progression of existing non-target lesion, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan Meier method was used.
| Months | Cohort 1 | Cohort 2 |
|---|---|---|
| Duration of Intracranial Response Based on ICR Assessment | NA (30.6 to NA) | NA (5.6 to NA) |
Duration of intracranial response: time from first documentation of CR or PR considering only lesions having disease site=brain to first documentation of PD or death due to any cause, whichever occurred first, participants who had at least 1 intracranial lesion.CR: disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in \<10mm.PR:\>=30% decrease in the sum of the longest dimensions of target lesions taking reference the baseline sum longest dimension. PD:\>=20% increase in sum of longest dimensions of target lesion or appearance of one or more new lesion. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5mm and for non-target lesion PD: unequivocal progression of existing non-target lesion, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan Meier method was used.
| Months | Cohort 1 | Cohort 2 |
|---|---|---|
| Duration of Intracranial Response Based on Investigator Assessment | NA (15.1 to NA) | NA (8.3 to NA) |
Time to tumor response was defined as the time from first dose to first documentation of objective tumor response CR or PR. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| Months | Cohort 1 | Cohort 2 |
|---|---|---|
| Time to Tumor Response Based on ICR Assessment | 1.4 (1.2 to 17.9) | 1.4 (1.2 to 6.9) |
Time to tumor response was defined as the time from first dose to first documentation of objective tumor response CR or PR. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| Months | Cohort 1 | Cohort 2 |
|---|---|---|
| Time to Tumor Response Based on Investigator Assessment | 1.4 (1.2 to 27.6) | 1.4 (1.2 to 17.9) |
AE:any untoward medical occurrence in a study participant administered a product or medical device;event did not necessarily have a causal relationship with treatment or usage.Serious AE:any untoward medical occurrence at any dose resulted in death;life-threatening;required inpatient or prolongation of existing hospitalization;persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important event.AEs were graded by the National Cancer Institute Common Terminology Criteria AE(NCICTCAE)v4.03 where,Grade(G)1:mild AE;G2:moderate;G3:severe;G4:life-threatening consequences,urgent intervention indicated;G5:death related to AE. Focus of AE summaries was on treatment-emergent AE(TEAE).AE was considered TEAE if the event occurred during the on-treatment period.On-treatment:time from first dose of study treatment through end of study follow-up(i.e.,up to 28 days after last dose of treatment. Participant with G3or4 and5 AEs were reported.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| All-causality TEAEs | 67 | 42 |
| Treatment-related TEAEs | 67 | 42 |
| All-causality serious AEs | 23 | 16 |
| Treatment-related serious AEs | 11 | 5 |
| All-causalities maximum Grade 3 or 4 AEs | 49 | 25 |
| Treatment-related Grade 3 or 4 AEs | 46 | 19 |
| All-causality Grade 5 AEs | 4 | 7 |
| Treatment-related Grade 5 AEs | 0 | 0 |
An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily have a causal relationship with the treatment or usage. The central-nervous system-related AEs included AEs under the cluster terms of mood effects, cognitive effects, psychotic effects, and speech effects.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Cognitive Effects | 2 | 1 |
| Mood Effects | 1 | 2 |
| Speech Effects | 0 | 1 |
| Psychotic Effects | 1 | 0 |
Laboratory tests included hematology, chemistry and lipids. Laboratory test results were graded according to NCI CTCAE version 4.03, where Grade 0: no AE, Grade 1 : mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Shifts from Grade \<=2 at baseline to Grade 3 or 4 post-baseline were considered clinically significant. Only categories with non-zero values were reported in this outcome measure.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Anemia: Grade 0 to Grade 3 or 4 | 3 | 0 |
| Anemia:Grade 1 to Grade 3 or 4 | 2 | 3 |
| Anemia:Grade 2 to Grade 3 or 4 | 1 | 1 |
| Lymphocyte count decreased Grade 0 to Grade 3 or 4 | 3 | 0 |
| Lymphocyte count decreased:Grade 1 to Grade 3 or 4 | 1 | 0 |
| Platelet count decreased: Grade 0 to Grade 3 or 4 | 2 | 1 |
| Alanine aminotransferase increased: Grade 0 to Grade 3 or 4 | 2 | 0 |
| Alanine aminotransferase increased:Grade 1 to Grade 3 or 4 | 2 | 0 |
| Alkaline phosphatase increased: Grade 0 to Grade 3 or 4 | 1 | 0 |
| Aspartate aminotransferase increased: Grade 0 to Grade 3 or 4 | 2 | 1 |
| Aspartate aminotransferase increased:Grade 1 to Grade 3 or 4 | 1 | 0 |
| Blood bilirubin increased: Grade 0 to Grade 3 or 4 | 1 | 0 |
| Blood bilirubin increased:Grade 1 to Grade 3 or 4 | 0 | 1 |
| CPK increased: Grade 0 to Grade 3 or 4 | 0 | 1 |
| CPK increased:Grade 2 to Grade 3 or 4 | 1 | 0 |
| Creatinine increased: Grade 0 to Grade 3 or 4 | 1 | 1 |
| GGT increased: Grade 0 to Grade 3 or 4 | 3 | 2 |
| GGT increased:Grade 1 to Grade 3 or 4 | 2 | 0 |
| Hypercalcemia: Grade 0 to Grade 3 or 4 | 0 | 1 |
| Hyperglycemia: Grade 0 to Grade 3 or 4 | 6 | 0 |
| Hyperglycemia:Grade 1 to Grade 3 or 4 | 1 | 1 |
| Hypermagnesemia: Grade 0 to Grade 3 or 4 | 7 | 1 |
| Hypocalcemia: Grade 0 to Grade 3 or 4 | 0 | 1 |
| Hypokalemia: Grade 0 to Grade 3 or 4 | 2 | 2 |
| Hypokalemia:Grade 2 to Grade 3 or 4 | 1 | 0 |
| Hyponatremia: Grade 0 to Grade 3 or 4 | 1 | 1 |
| Hyponatremia:Grade 1 to Grade 3 or 4 | 0 | 1 |
| Hypophosphatemia: Grade 0 to Grade 3 or 4 | 4 | 1 |
| Hypophosphatemia:Grade 1 to Grade 3 or 4 | 0 | 1 |
| Lipase increased: Grade 0 to Grade 3 or 4 | 5 | 2 |
| Lipase increased:Grade 1 to Grade 3 or 4 | 1 | 0 |
| Serum amylase increased: Grade 0 to Grade 3 or 4 | 1 | 1 |
| Cholesterol high: Grade 0 to Grade 3 or 4 | 12 | 1 |
| Cholesterol high:Grade 1 to Grade 3 or 4 | 6 | 3 |
| Cholesterol high:Grade 2 to Grade 3 or 4 | 1 | 0 |
| Hypertriglyceridemia: Grade 0 to Grade 3 or 4 | 19 | 3 |
| Hypertriglyceridemia:Grade 1 to Grade 3 or 4 | 9 | 6 |
| Hypertriglyceridemia:Grade 2 to Grade 3 or 4 | 3 | 1 |
Vital signs evaluation included diastolic blood pressure (DBP), systolic blood pressure (SBP), pulse rate and weight. Blood pressure and pulse rate were recorded in sitting position after the participant had been sitting quietly for at least 5 minutes. The pre-specified criteria included: sitting SBP change \>=40 millimeters of mercury (mmHg) increase, \>=40 mmHg decrease; sitting DBP change \>=20 mmHg increase, change \>=20 mmHg decrease, or change \>=60 mmHg increase; sitting pulse rate value \<50 beats per minute (bpm), \>120 bpm, change \>=30 bpm increase, or change \>=30 bpm decrease; weight 10% \<= change \<20% increase, change \>=20% increase or change \>=10% decrease. One participant can have more than one vital sign data meeting pre-specified criteria.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Sitting SBP change >=40 mmHg increase | 10 | 1 |
| Sitting SBP change >=40 mmHg decrease | 2 | 0 |
| Sitting DBP change >=20 mmHg increase | 26 | 10 |
| Sitting DBP change >=20 mmHg decrease | 12 | 7 |
| Sitting DBP change >=60 mmHg increase | 0 | 0 |
| Sitting pulse rate value <50 bpm | 0 | 0 |
| Sitting pulse rate value >120 bpm | 5 | 3 |
| Sitting pulse rate change >=30 mmHg increase | 18 | 5 |
| Sitting pulse rate change >=30 mmHg decrease | 5 | 7 |
| weight 10% <= change <20% kg increase | 43 | 22 |
| Weight change >=20% kg increase | 14 | 6 |
| Weight change >=10% kg decrease | 3 | 2 |
The QT intervals were corrected for heart rate (QTc) using standard correction factors (ie, QTcF \[Fridericia's\], QTcB \[Bazett's\], and possibly a study-specified factor, as appropriate). The pre-specified criteria included: PR interval change \>= 50% and baseline \<200 msec, change \>=25% and baseline \>=200 msec; QRS interval change \>=50% and baseline \<100 msec, change \>=25% and baseline \>=100 msec; QTcB values \<=450 msec, 450 \< Value \<= 480 msec, 480 \< Value \<= 500 msec, value \>500 msec, change \<=30 msec, 30 \< Change \<= 60 msec, change \>60 msec; QTcF value \<=450 msec, 450 \< Value \<= 480 msec, 480 \< Value \<= 500 msec, Value \> 500 msec, change \<=30 msec, 30 \< Change \<=60 msec and change \>60 msec. . One participant can have more than one ECG data meeting pre-specified criteria.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| PR interval change >=50% and baseline <200 msec | 4 | 1 |
| PR interval change >=25% and baseline >=200 msec | 0 | 0 |
| QRS interval change >=50% and baseline<100 msec | 1 | 1 |
| QRS interval change >=25% and baseline >=100 msec | 2 | 0 |
| QTcB value <=450 msec | 27 | 27 |
| QTcB 450 < Value <= 480 msec | 26 | 9 |
| QTcB 480 < Value <= 500 msec | 5 | 3 |
| QTcB value >500 msec | 9 | 3 |
| QTcB change <=30 msec | 31 | 25 |
| QTcB 30 < Change <= 60 msec | 24 | 14 |
| QTcB change >60 msec | 12 | 3 |
| QTcF value <=450 msec | 49 | 35 |
| QTcF 450 < Value <= 480 msec | 13 | 6 |
| QTcF 480 < Value <= 500 msec | 1 | 1 |
| QTcF value >500 msec | 4 | 0 |
| QTcF change <=30 msec | 39 | 29 |
| QTcF 30 < Change <= 60 msec | 20 | 9 |
| QTcF change >60 msec | 8 | 4 |
Echocardiogram or multigated acquisition scan were performed to monitor LVEF. Pre-specified criteria included shift from baseline normal to post-baseline below lower limit of normal (LLN) \>=20-point decrease from baseline in LVEF% .
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| LVEF change from baseline normal to post-baseline below LLN | 7 | 0 |
| LVEF >=20-point decrease from baseline | 3 | 0 |
The loratinib Cmax was estimated using non-compartmental analysis.
| nanogram per milliliter (ng/mL) | Cohort 1 | Cohort 2 |
|---|---|---|
| Cycle 1 Day 1 Maximum Plasma Concentration (Cmax) | 1004 ± 42 | 1074 ± 58 |
The loratinib Tmax was estimated using non-compartmental analysis.
| hour | Cohort 1 | Cohort 2 |
|---|---|---|
| Cycle 1 Day 1 Time to Cmax (Tmax) | 1.02 (0.500 to 3.12) | 1.45 (0.483 to 4.00) |
The loratinib AUCtau was estimated using non-compartmental analysis.
| nanogram*hour per milliliter (ng.hr/mL) | Cohort 1 | Cohort 2 |
|---|---|---|
| Cycle 1 Day 1 Area Under the Plasma Concentration Versus Time Profile Within A Dose Interval (AUCtau) | 7310 ± 17 | 7778 ± 39 |
The loratinib Cmax was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.
| ng/mL | Cohort 1 | Cohort 2 |
|---|---|---|
| Steady-State Cmax | 643.9 ± 50 | 795.9 ± 40 |
The loratinib Tmax was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.
| hour | Cohort 1 | Cohort 2 |
|---|---|---|
| Steady-State Tmax | 1.53 (0.533 to 3.03) | 1.88 (0.500 to 8.02) |
The loratinib AUCtau was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.
| ng*hr/mL | Cohort 1 | Cohort 2 |
|---|---|---|
| Steady-State AUCtau | 5388 ± 37 | 6801 ± 40 |
The loratinib CL/F was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.
| Liter per hour (L/hr) | Cohort 1 | Cohort 2 |
|---|---|---|
| Apparent Clearance (CL/F) | 18.55 ± 37 | 14.71 ± 40 |
The loratinib Rac was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.
| Ratio | Cohort 1 | Cohort 2 |
|---|---|---|
| Observed Accumulation Ratio (Rac) | 0.7371 ± 47 | 0.9578 ± 33 |
Collected over From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 28/67 (41.8%) | 23/67 (34.3%) | 67/67 (100%) |
| Cohort 2 | 26/42 (61.9%) | 16/42 (38.1%) | 42/42 (100%) |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| PneumoniaInfections and infestations | 3/67 | 5/42 |
| PyrexiaGeneral disorders | 0/67 | 2/42 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/67 | 2/42 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/67 | 0/42 |
| Cerebral infarctionNervous system disorders | 2/67 | 0/42 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/67 | 0/42 |
| DeathGeneral disorders | 0/67 | 1/42 |
| Sudden deathGeneral disorders | 0/67 | 1/42 |
| Liver injuryHepatobiliary disorders | 0/67 | 1/42 |
| Febrile infectionInfections and infestations | 0/67 | 1/42 |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| HypertriglyceridaemiaMetabolism and nutrition disorders | 60/67 | 32/42 |
| Weight increasedInvestigations | 49/67 | 19/42 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 41/67 | 29/42 |
| Aspartate aminotransferase increasedInvestigations | 40/67 | 18/42 |
| Alanine aminotransferase increasedInvestigations | 38/67 | 19/42 |
| AnaemiaBlood and lymphatic system disorders | 31/67 | 15/42 |
| HyperglycaemiaMetabolism and nutrition disorders | 31/67 | 6/42 |
| Blood cholesterol increasedInvestigations | 29/67 | 14/42 |
| Gamma-glutamyltransferase increasedInvestigations | 28/67 | 12/42 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 21/67 | 9/42 |
| Age, Continuous(Years) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 50.4 ± 10.85 | 52.1 ± 13.36 | 51.0 ± 11.84 |
| Age, Customized(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 61 | 35 | 96 |
| >65 years | 6 | 7 | 13 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 33 | 23 | 56 |
| Male | 34 | 19 | 53 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Asian — Chinese | 67 | 42 | 109 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2019 to primary completion in Aug 2020, 15 months.
Results were first posted in Oct 2021, 1 year 2 months after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 15 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorlatinib
Carcinoma, Non-Small-Cell Lung →